Logo

Merck Signs a Clinical Trial Collaboration with FLX Bio- for a Combination Therapy

Share this

Merck Signs a Clinical Trial Collaboration with FLX Bio- for a Combination Therapy

Shots:

  • The agreement involves assessing of FLXBio’s  FLX475 candidate with Merck’s Keytruda (pembrolizumab) in the ongoing P-I/II as an anti-PD-1 therapy in patients with multiple types of cancer
  • The study will evaluate efficacy- safety & tolerability of FLX475 as a monothx and in combination with Keytruda in various centers including the US- Australia and Asia
  • FLX475 PO is a novel inhibitor of CCR4- while promoting anti-tumor immune response

 Ref: FLX Bio | Image: Merck


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions